Sumitomo Pharma Co., Ltd.
4506
Kedudukan dalam Saham
#3233
Sumitomo Pharma Co., Ltd. is a global company involved in the creation,... Sumitomo Pharma Co., Ltd. is a global company involved in the creation, production, and sale of a variety of products, including human pharmaceuticals, food ingredients and additives, and veterinary medicines. Its operations span across Japan, North America, China, and other international territories. The company's pharmaceutical offerings address a broad spectrum of medical needs. These include treatments for conditions such as Parkinson's disease, depression, type 2 diabetes, systemic fungal infections, hypertension, pruritus, chronic obstructive pulmonary disease (COPD), angina pectoris, and arrhythmia. Additionally, they manufacture atypical antipsychotics, antiepileptics, carbapenem antibiotics, gastrointestinal products, and specialized medications for Anderson-Fabry disease. Beyond healthcare, Sumitomo Pharma provides food components and enhancement agents like polysaccharides, along with savory flavorings such as soups and bouillons. The company also supplies chemical raw materials, which encompass pharmaceutical excipients, components for personal care products, substances used in coatings and industrial applications, and electronic materials. Moreover, it produces veterinary therapeutic solutions designed for domestic pets, specifically dogs and cats, as well as for various farm animals, including cattle, swine, poultry, horses, and cultivated fish. To drive innovation, Sumitomo Pharma fosters partnerships with several organizations. These collaborators include Healios K.K., Keio University, RIKEN, the Center for iPS Cell Research and Application, Kyoto University, and Aikomi Co., Ltd. The company also maintains a joint development agreement with SanBio Company Limited, a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd., and a strategic alliance with Roivant Sciences Ltd. Originally established in 1897, the company, headquartered in Osaka, Japan, was known as Sumitomo Dainippon Pharma Co., Ltd. until it adopted its current name, Sumitomo Pharma Co., Ltd., in April 2022. It functions as a subsidiary of Sumitomo Chemical Company, Limited.
Harga Saham
$12.28
Modal Pasaran
$5.51B
Perubahan (1 hari)
0.59%
Perubahan (1 tahun)
8.21%
Negara
JP
Perdagangan Sumitomo Pharma Co., Ltd. (4506)
Kategori
Healthcare
Pendapatan untuk Sumitomo Pharma Co., Ltd. (4506)
Pendapatan pada Jun 2026 TTM: $696.20M
Menurut laporan kewangan terkini Sumitomo Pharma Co., Ltd., pendapatan semasa syarikat ialah $696.20M. Pada tahun 2024, syarikat memperoleh pendapatan sebanyak $-2.13B, penurunan berbanding pendapatan pada tahun 2023 yang berjumlah $-360.91M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Sumitomo Pharma Co., Ltd. dari 2005 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $696.20M | 492.57% |
| 2025 | $117.49M | -105.50% |
| 2024 | $-2.13B | 491.50% |
| 2023 | $-360.91M | -152.97% |
| 2022 | $681.35M | -3.06% |
| 2021 | $702.89M | -9.98% |
| 2020 | $780.81M | 33.24% |
| 2019 | $586.00M | -26.64% |
| 2018 | $798.75M | 88.42% |
| 2017 | $423.92M | 20.57% |
| 2016 | $351.60M | 24.93% |
| 2015 | $281.43M | -16.37% |
| 2014 | $336.52M | 74.64% |
| 2013 | $192.69M | -2.09% |
| 2012 | $196.80M | -34.88% |
| 2011 | $302.19M | -10.14% |
| 2010 | $336.28M | 2.87% |
| 2009 | $326.90M | -21.37% |
| 2008 | $415.75M | 27.67% |
| 2007 | $325.63M | 49.13% |
| 2006 | $218.36M | 100.02% |
| 2005 | $109.17M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 153.46% |
IN
|
